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Background:  To date, there is no comprehensive systematic review and meta-analysis to assess the suitability of 
COVID-19 vaccines for mass immunization. The current systematic review and meta-analysis was conducted to 
evaluate the safety and immunogenicity of novel COVID-19 vaccine candidates under clinical trial evaluation and 
present a contemporary update on the development and implementation of a potential vaccines.  
Methods: For this study PubMed, MEDLINE, and Embase electronic databases were used to search for eligible 
studies on the interface between novel coronavirus and vaccine design until December 31, 2020.  
Results: We have included fourteen non-randomized and randomized controlled phase I-III trials. Implementation of 
a universal vaccination program with proven safety and efficacy through robust clinical evaluation is the long-term 
goal for preventing COVID-19. The immunization program must be cost-effective for mass production and 
accessibility. Despite pioneering techniques for the fast-track development of the vaccine in the current global 
emergency, mass production and availability of an effective COVID-19 vaccine could take some more time. 
Conclusion: Our findings suggest a revisiting of the reported solicited and unsolicited systemic adverse events for 
COVID-19 candidate vaccines. Hence, it is alarming to judiciously expose thousands of participants to COVID-19 
candidate vaccines at Phase-3 trials that have adverse events and insufficient evidence on safety and effectiveness that 
necessitates further justification.  






Since December 2019, the world has been experiencing a life-
changing pandemic caused by the coronavirus disease 2019 
(COVID-19) and its associated etiological agent, i.e., severe 
acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [1,2]. 
As of December 27, 2020, this virus had infected more than 79.2 
million people and resulted in over 1.7 million fatalities across 
the globe [3]. The deaths toll resulted from the novel 
coronavirus infection affected most developed and developing 
countries worldwide, but it has severely impacted on 
developing countries, such as Brazil, where vulnerable people 
are more likely to be associated with coronavirus-related 
mortality [4]. Therefore, there is an urgent need to prevent 
COVID-19 infection with the implementation of a safe and 
effective vaccination program as well as the development of 
potential therapeutic interventions for treatment.  
The primary long-term focus to control the COVID-19 
pandemic is implementing a universal SARS-CoV-2 
vaccination program that proves safety, efficacy, and cost-
effective [5]. To date, there are several potential vaccine 
candidates in the developmental stage (162 candidate vaccines 
in preclinical evaluation) (Figure 1a & b) [6]. However, the 
estimated earliest availability of the possible COVID-19 
vaccine is by 2021 [7]. For instance, the Department of Health 
and Human Services in the United States has initiated the 
'Operation Warp Speed' which is based on a public-private 
partnership that is utilizing different pathways to manufacture 
and deliver a safe and effective vaccine aiming to distribute 
more than 300 million doses by the beginning of 2021 [8]. 
Based on the evidence from earlier pandemics, careful planning 
for the COVID-19 vaccination program is crucial to ensure 
readiness and accessibility for both public and the healthcare 
community. To date, only a few comprehensive review articles 
have evaluated the suitability of candidate vaccines under 
different phases of evaluation or collated data from ongoing 
SARS-CoV-2 immunization programs. Therefore, we have 
conducted the present study to assess the safety and 
immunogenicity of the novel COVID-19 vaccine candidates 
and present a contemporary update on the development and 
implementation of potential vaccine candidates for COVID-19. 
Methodology  
The current systematic review followed the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) 
Statement and Meta-analyses of Observational Studies in 
Epidemiology (MOOSE) reporting guidelines [9,10]. We 
prospectively registered the review protocol on Open Science 
Framework (#osf.io/2jp73/). We have searched (from January 1 
to December 31, 2020) MEDLINE (via Ovid platform), 
PubMed, Embase, Cochrane, clinicaltrials.org and Google for 
timely reports using different combinations of keywords such 
as “2019-nCoV”; “SARS-CoV-2”; “Coronavirus Disease 
2019”; “COVID 19”; “Vaccine”;   “2019 Novel Coronavirus 
Vaccine”; “2019-nCoV vaccine”; “SARS2 vaccine”; “SARS-
CoV-2 vaccine”; “Coronavirus Disease 2019 vaccine” and 
“COVID 19 vaccine”. Furthermore, we hand-searched the 
reference list from eligible studies and electronic databases of 
specific institutional websites and bibliographies (The Lancet, 
The Journal of the American Medical Association, and New 
England Journal of Medicine) for potentially relevant 
publications. 
Inclusion/exclusion criteria 
We considered studies of any design or any setting which 
evaluated the safety and security of COVID-19 immunization 
among non-exposed patients to SARS-CoV-2. We included 
only full-text available studies published in English. 
Commentaries, letters to the editor, and review articles were 
excluded. We have collected the data from eligible studies on 
the topic of integrative review associated with developing and 
implementing a new vaccine against coronavirus. We 
performed an analysis of the most critical issues addressed.  
Outcomes 
Outcomes of interest were the presence of side-effects 
following immunization with COVID-19 vaccination 
candidates. We defined a medical severe adverse event as any 
untoward medical contingency that, at any dose, resulted in 
death, was life-threatening, required hospitalization, or resulted 
in persistent or significant disability or incapacity. We have 
mainly analyzed the solicited systemic adverse events (AE).  
However, some of these studies have recorded unsolicited 
adverse effects and local site reactions, which were not analyzed 
due to missing information. Also, serious adverse events were 
recorded, and the intensity of adverse events was categorized as 
mild, moderate, severe, and potentially life-threatening. 
Solicited AE refers to the data collected as part of the uniform 
collection of information whereas Unsolicited AE refers to 
information that is volunteered or noted in an unsolicited 
manner and not as a required data collection element. 
Data extraction 
Initially, titles of unique records identified in the systematic 
search were screened, and, during the full-text evaluation stage, 
short-listed relevant titles were assessed in detail for suitability 
of inclusion. Details regarding authors, study setting and period, 
the origin of studies, sample size, distribution of age and gender, 
target population, interventions, and outcome measures were 
extracted. The included articles comprised either single or 
multi-center studies. Four independent review authors (BS, 
MA, IB, and ABP) assessed the first and second stage 




conflict was resolved by group discussion and the establishment 
of a consensus.  
Data Analysis and Synthesis 
Prevalence was calculated for categorical variables. The 
decision to select either the fixed-effect or random-effects 
model relied on the findings of the statistical tests for 
heterogeneity. The Cochrane Q homogeneity test was utilized 
to assess the data heterogeneity (significance set at p < 0.10). 
The fixed-effect model was considered if the studies were found 
statistically homogeneous. A random-effects model was 
utilized for studies having statistical heterogeneity. The 
Higgin's I2 test is the ratio of true heterogeneity to the total 
variation in observed effects [11]. A rough guide for the 
interpretation of I2 test is as follows: 0-25% (might not be 
significant); 25-50% (may represent moderate heterogeneity); 
50-75% (may represent substantial heterogeneity) and >75% 
(considerable heterogeneity). Publication bias was visually 
estimated by analyzing the funnel plots. Pooled estimates were 
calculated using R 3.5.1 software. Two independent reviewers 
(ABP and BS) evaluated the methodological quality of the 
included RCTs using the Cochrane Risk of Bias Tool 2.0 of 
RevMan version 5.3 (The Cochrane Collaboration, 
Copenhagen, Denmark) as high, low, or unclear for each item. 
Eligible studies were assessed on the following items: Bias 
arising from the randomization process, bias due to deviations 
from intended interventions, bias due to missing outcome data, 
bias in measurement of the outcome and bias in selection of the 
reported results. While non-randomized studies were evaluated 
through the Risk of Bias in Non-randomized Studies - of 
Interventions ( ROBINS-I) tool [12,13] assessing cofounding, 
selection of participants, classification of interventios, deviation 
of intented interventions, missing data, measures of outcomes 
and selection of reported results. 
Results 
The literature search resulted in a total of 3,695 articles, of 
which 3,629 were identified as non relevant topic/title and 
duplicates that were excluded on initial screening. A detailed 
evaluation of the relevant titles and abstracts based on inclusion 
and exclusion criteria led to further exclusion of 52 articles from 
the analysis (Table 1, Figure 2). Finally, fourteen studies that 
have assessed the safety of COVID-19 vaccination candidates 
were included in the current systematic review [14-27]  and 
twelve for the meta-analysis [14,15,17-20,22-24,26,27].  
Quality assessment and Publication Bias 
The risk of bias was assessed for primary outcomes in eleven 
included randomized control trials using five domains. Figures 
(3a-d) show the summary and graph, respectively. The 
Cochrane Risk of Bias 2.0 tool contains five entries related to 
bias arising from the randomization process, bias due to 
deviations from intended interventions, bias due to missing 
outcome data, bias in measurement of the outcome and bias in 
selection of the reported results. Three of the studies [25-27]  
met the criteria for low risk of bias across all domains, under 
the general heading of randomization to the vaccine 
administration or placebo, sequence generation 100% percent 
of the studies were adequately randomized, and at allocation 
concealment, 60% the studies were considered a low risk of bias 
and the rest unclear because of unsufficient detail. No studies 
reported a high risk of bias under blinded assessment of 
outcome by the administration, minimizing detection bias, but 
in two studies it was high whether the caregivers and 
researchers were blinded to the treatment group [17, 24] For 
missing outcome data, 80% of the studies were at low risk. 
Under the domain for bias in measurement of the outcome, all 
studies were considered low risk of bias because they reported 
an existing protocol, followed, and initially reported the chosen 
outcomes. For bias in the selection of the reporting results, nine 
studies were low risk, and the other two remained unclear, and 
for other biases, eleven studies had low risk because they did 
not state any important concerns about bias not covered by other 
domains in the tool. For the three were non-randomized open-
label trials we assessed the quality through the ROBINS-I tool, 
one presented unclear risk on the measures of the outcomes and 
the rest of the domains on the studies had a low risk on bias 
under cofounding, selection of participants, classification of 
intended interventions, missing data and selection of reported 
results, This reflects the quality and under which rigor vaccine 
trials are being runned. 
Outcome measures  
Among the included 12 studies for meta analysis, 13087 total 
adverse events were reported from the vaccinated 47019 
population. Figure 4a depicts the meta-analysis related to total 
adverse events among the vaccinated population. The pooled 
total adverse events was 35%, (95% CI: 26-44%). 
Heterogeneity among included studies 
The findings for the heterogeneity test for this meta-analysis to 
look for the association between the COVID-19 vaccine and 
total adverse events are displayed towards the bottom of the 
forest plot in the line. For total adverse events (Q [χ2] =768.30, 
P=0.001, I2=99%, tau2=0.105 (Figure 4a). As the I2 was >25%, 
a random effect model was considered. Tau2 reflects the 
presence of true heterogeneity among the studies.  
Publication bias and funnel plots 
The sensitivity analysis for the above finding demonstrated 
consistent results. Based on a visual inspection of the funnel 
plot, there was evidence of publication bias for the included 
studies (Figure 4b). The funnel plots indicated the presence of 






Overview of the human trials for COVID-19 vaccine  
Table 1-4 shows the characteristics safety, and immunogenicity 
outcomes of included studies [14-27]. Zhu et al. [14] conducted 
the first vaccine trial in Wuhan, China, a phase-1, single-center, 
non-randomized, open-label trial of a recombinant adenovirus 
type-5 (Ad5) vectored COVID-19 vaccine that uses dose-
escalation. This study enrolled healthy adults (18-60 years) who 
were sequentially given one of the three doses of vaccine, i.e. 
5×1010, 1×10¹¹, and 1·5×10¹¹ viral particles assessed for safety, 
tolerability, and immunogenicity (ClinicalTrials.gov, 
NCT04313127). The primary outcome measured was the 
occurrence of adverse events within seven days post-
vaccination. The overall safety of the vaccine was also 
monitored after 28 days of vaccination. The immunogenicity 
was assessed by measuring the binding antibody responses for 
the receptor-binding domain and spike glycoprotein, the level 
of neutralizing antibodies produced in response to the 
vaccination, and the response of T-cell proliferation. In this 
study, a higher proportion of subjects in the low and middle-
dose group (83% each) and 75% in the high-dose group had at 
least one adverse reaction within the first seven days post-
vaccination. The most frequently observed recurring adverse 
events for all groups were of mild-to-moderate severity, which 
mainly included fever (46%), fatigue (44%), headache (39%), 
and myalgia (17%). The specific (humoral) antibody response 
against SARS-CoV-2 significantly elevated at day-14 and 
peaked at 28 days after vaccination, whereas the T-cell response 
attains the peak on the 14th  day after vaccination. The trial's 
findings showed promising results in terms of tolerability and 
immunogenicity of this candidate vector-based COVID-19 
vaccine after 28 days of vaccination. A subsequent randomized, 
double-blinded phase-2 study by Zhu et al. [15] of the same 
COVID-19 vaccine in 508 participants assessed the safety and 
immunogenicity. The authors demonstrated that this vaccine is 
safe and showed marked immunogenicity in most subjects 
administered with a single dose. Therefore, the candidate 
COVID-19 vaccine (5 × 10¹⁰ viral particles) should be tested in 
a phase 3 effectiveness trial on healthy individuals. Another 
Phase-1 trial by Jackson et al. [16] enrolled 45 participants to 
test the RNA-based vaccine's safety and immunogenicity. 
Subjects in the higher dose group had higher antibody response, 
and greater than half the participants were reported to have 
solicited adverse events. All the participants had developed 
immunogenicity against SARS-CoV-2. There were no safety 
issues related to the trial, which support the advancement of this 
candidate vaccine for testing in a more significant number of 
participants. Folegatti et al. [17] conducted a single-blind, phase 
1/2, randomized controlled trial to assess the safety, 
reactogenicity, and immunogenicity of the adenovirus-vectored 
vaccine (ChAdOx1 nCoV-19) and compare it with a 
meningococcal conjugate vaccine (MenACWY) as control. The 
candidate vaccine demonstrated considerable safety, humoral, 
and cellular immune responses and thus can be considered for 
further largescale evaluation as a phase 3 trial. Xia et al. [18] 
published an interim analysis of two randomized trials of 
inactivated vaccine, which reported a lesser frequency of 
adverse events and acceptable immunogenicity of the candidate 
vaccine in this ongoing study. A phase 2 single-blind, 
randomised, controlled, phase 2/3 trial conducted by Ramasamy 
et al. [19] reported that ChAdOx1 nCoV-19 was better tolerated 
in older adults than in younger adults and has analogous adverse 
effects  across all age groups after a boost dose. Xia et al. [20] 
conducted a randomised, double-blind, placebo-controlled, 
phase 1/2 trial in Henan Province of China on BBIBP-CorV 
vaccine. The BBIBP-CorV was found safe and well tolerated in 
all tested doses. Humoral responses were developed 42 days 
post-immunization.[20] A phase 1, open-label trial published in 
the  New England Journal of Medicine, conducted by Anderson 
et al.[21] on safety and immugenicity of COVID-19 mRNA-
1273 vaccine reported that the vaccine  produced mild to 
moderate adverse effects.  A randomized, placebo-controlled, 
phase 1–2 trial conducted by Keech et al. [22] on safety and 
immunogenicity of the rSARS-CoV-2 vaccine (NVX-
CoV2373),  35 days post-immunization with the vaccine was 
found safe ( there was no series adverse effects)  and immune 
response was elicited.  In a placebo-controlled, observer-
blinded dose-escalation study on 45 healthy volunteers 
conducted by Mulligan et al. [23]  found that BNT162b1 
produced dose-dependent local and systemic adverse effects, 
which were transient and mild to moderate in nature. Walsh et 
al.[24] conducted a placebo-controlled, observer-blinded, dose-
escalation, phase-1 trial on two RNA based vacines 
(BNT162b1and BNT162b2). In older patients BNT162b2 
initiated to produce lesser systemic adverse effects in contrast 
to BNT162b1 vaccine. [24]. Zhang et al.[25] conducted a 
randomized, double-blind, placebo-controlled, phase I/II 
clinical trial in Beijing, China which suggested for efficacy 
assessment of CoronaVac in future in phase 3 trials at a trivial 
dose of 3 μg considering the safety, immunogenicity, and 
production capacity. Polack et al. [26] reported that the RNA 
vaccine (BNT162b2) was 95% effective against the virus; 
whereas according to Che et al., [27] adults who obtained the 
inactivated SARS-CoV-2 vaccine had NAb as well as anti-S/N 
antibody and experienced few side effects. In addition to these 
published studies on testing the safety and immunogenicity of 
COVID-19 candidate vaccines, 162 other ongoing candidate 






Figure 1a: Candidate vaccines in preclinical evaluation (n=162) 
 
 





































































































Trial type Country Recruitme
nt dates 














phase 1 trial 
China March 16 - 
27, 2020 
108 55/53 18-60 (mean 36.3) Healthy 
adults [5 × 
10¹⁰ dose 
(n=36); 1 × 
10¹¹ dose 
(n=36); 1.5 











phase 2 trial 
China April 11 
and 16, 
2020 
508 254/254 18–83 (39·7±12.5) Healthy 
adults [1 × 
10¹¹ dose 
(n=253); 5 






et al. [16] 





US March 16 
and April 
14, 2020 









et al. [17] 






UK April 23 
and May 21, 
2020 













clinical trial  
China April 12 
and May 2, 
2020 
96 38/58 41.2 ±9.6 Healthy 
adults (4 
groups) 











 China  April 12 
and May 2, 
2020 














UK May 30 and 
Aug 8, 2020 
560 280/280 Gp1:43 years (IQR 
33·6–48·0), Gr2: 60 
years (57·5–63·0) and 













phase 1 trial 
China April 29 
and June 28, 
2020, 












phase 2 trial 
China May 18 and 
July 30, 
2020 





n, et al. 
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and May 12, 
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to age (56 
to 70 years 
or ≥71 
years) 25 











Australia May 27 and 
June 6, 
2020 












































phase 1 trial 
United 
States 
May 4 and 
June 22, 
2020, 
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Mild in 69 (21 
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Severe in 2 
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day 0, 7, 
14, and 
28  
At least one systemic 
symptom after prime 
vaccination with the 
standard dose of ChAdOx1 
nCoV-19 by 42 (86%) of 
49 participants in the 18–
55 years group, 23 (77%) 
of 30 in the 56–69 group, 
and 32 (65%) of 49 in the 










2 0 and 28 2 μg, 4 















1/2 8 μg on day 0 or on a 
two-dose schedule of 4 
μg on days 0 and 14, 0 
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2 0 and 21 10 μg, 30 







7, 21, 28 
and 35 
days 
25% (3/12 in  10-μg group) 
to 50% (6/12 each in 30-μg 
and 100-μg groups) of 
individuals who received 
BNT162b1 and by 11.1% 
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18–55 years of age 
10 μg (3/12) 20 μg (4/12) 
30 μg (6/12) 100 μg (6/12) 
Placebo (1/12) 
65–85 years of age 
10 μg (3/12) 20 μg (4/12) 
30 μg (2/12) Placebo (1/9) 
 
BNT162b2 





10 μg (2/12) 20 μg (4/12) 
30 μg (3/12) 100 μg (0/0) 
Placebo (1/9) 
65–85 years of age 
10 μg (0/12) 20 μg (1/12) 
















day 0 and 
day 14, or 
day 0 and 
day 28 












3 μg group (6/24); 6 μg 
group (6/24); Placebo 
group (2/24). 
Dose 2 
3 μg group (1/24); 6 μg 





3 μg group (22/120); 6 μg 
group (21/120); Placebo 
group (9/60). 
Dose 2 
3 μg group (7/117); 6 μg 




3 μg group (1/24); 6 μg 
group (2/24); Placebo 
group (0/24). 
Dose 2 
3 μg group (0/24); 6 μg 





3 μg group (22/120); 6 
μg group (21/120); 
Placebo group (9/60). 
Dose 2 
3 μg group (0/117); 6 μg 












Systemic events were 
reported more often by 
younger vaccine recipients 
(16 to 55 years of age) than 
by older vaccine recipients 
(age 55 +) in the 
reactogenicity subset and 
more often after dose 2 than 
dose 1. Most common 
reported systemic events 
were fatigue and headache 
(59% and 52%, 
respectively, after the 
second dose, among 
younger recipients; 51% 
and 39% among older 
recipients) 





















7 days after first and 
second immunizations, 
mainly slight fatigue and 
fever in 10%, 13%, and 
14.7% of individuals in the 
medium-dose, high-dose, 
and placebo groups, 
respectively 
0-28 procedure: 
7 days after the first and 
second immunizations, 
mainly including slight 
Overall adverse reaction 
rates during the 28 days 
after immunization were 
24%, 27.3%, and 17.3% 
(0, 14 procedure) and 
27.3%, 19.3%, and 12% 
(0, 28 procedure) in the 
mediumdose, high-dose, 





fatigue and fever, were 
reported in 13.3%, 8%, and 
9.3% of individuals 
 
 
Table 3: Percentage of Total Adverse and Serious Adverse Events 
 
Table 3: Percentage of Total Adverse and Serious Adverse Events 
 
Author Vaccine Total Adverse events * 
%(N) 
Total Serious Adverse 
Events ** 
 %(N) 
Zhu, et al. [14] adenovirus type-5 (Ad5)-
vectored 
81 (87/108) - 
Zhu, et al. [15] adenovirus type-5 (Ad5)-
vectored 
60% (305/508) 6.5 (25/382) 
Jackson, et al. [16] mRNA (mRNA-1273) First dose: 53% (24/45) 
Second Dose: 80% (36/45) 
0 (0/45) 
Folegatti, et al. [17] ChAdOx1 nCoV-19 
(SARS-CoV-2) vs. 
MenACWY (Control) 
53% (570/1077) 0 (0/1077) 





 Xia, et al. [18] Inactivated COVID-19 
vaccine (Phase-II) 
13% (28/224) - 
Ramasamy, et al. [19] ChAdOx1 nCoV-19 
(SARS-CoV-2) vs. 
MenACWY (Control) 
17.3% (97/560) - 
Xia, et al. [20]  BBIBP-CorV 29.2(42/144) 0(0/144) 
Xia, et al. [20] BBIBP-CorV - - 
Anderson, et al. [21] mRNA (mRNA-1273) First Dose: 40% (16/40) 
Second dose: 63% (25/40) 
Unsolicited Events irrespective 
of Dosing: 43%(17/40) 
- 
Keech, et al. [22] full-length wild-type SARS-
CoV-2 spike glycoprotein 
32% (42/131) - 
Mulligan, et al. [23] BNT162 mRNA 
vaccine candidates 
63% (15/24) - 
Walsh, et al. [24] BNT162b1 and BNT162b2 26% (41/156) - 
Zhang, et al. [25] CoronaVac (an inactivated 
vaccine candidate) 
Phase 1: 
Dose 1:31% (15/48) 
Dose 2: 13% (6/48) 
Phase 2: 
Dose 1: 18% (43/240) 
Dose 2: 7% (17/235) 
 
- 
Polack, et al. [26] mRNA 27% (11678/43252) 0.01(4/43252) 
Che, et al. [27] Inactivated Vaccine 24.5(146/595) 0(0/595) 
 
 
*Total Adverse Events = the total number of solicited and unsolicited adverse events from first dose till follow-up 





Table 4: Immunogenicity outcomes and conclusion of included studies 
 
 
Study   
Seropositivity rates of anti–SARS-
CoV-2 IgG ELISA  
 
Neutralizing antibody responses 
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- The Ad5 vectored COVID-19 
vaccine is tolerable and 
immunogenic at 28 days post-
vaccination. Humoral responses 
against SARS-CoV-2 peaked at 
day 28 post-vaccination in 
healthy adults, and rapid specific 
T-cell responses were noted 
from day 14 post-vaccination. 

































- Findings support testing of the 
Ad5-vectored COVID-19 
vaccine at 5 × 10¹⁰ viral particles 
in a phase 3 effectiveness trial in 
healthy adults. 
Jackson, 


























-   
The 25-μg and 100-μg 
doses elicited CD4 T-
cell responses 
  
100-μg dose elicits high neutralization 
responses and Th1-skewed CD4 T cell 
responses, coupled with a reactogenicity 
profile that is more favorable than that of 
the higher dose. 
Folegatti, 






























ChAdOx1 nCoV-19 showed an 
acceptable safety profile, and 
homologous boosting increased 
antibody responses 


























   
The blood lymphocyte 
subset and cytokine 
analysis showed no 
notable changes over 
time in different groups 
or substantial 
differences across 
groups at a certain time 
point. 
  
This interim report of the phase 1 and 
phase 2 trials of an inactivated COVID-
19 vaccine showed that patients had a low 
rate of adverse reactions and 
demonstrated immunogenicity; the study 
is ongoing. 
  













   
Ramasam
y, et al 
.[19] 
At both dose levels, and for all dose 
groups combined, anti-spike IgG 
responses at day 28 decreased with 
increasing age. 
Low-dose groups: 18–55 years, 
median 6439 arbitrary units [AU]/mL 
[IQR 4338–10 640], n=49; 56–69 
years, 4553 AU/mL [2657–12 462], 
n=60; ≥70 years, 3565 AU/mL 
[1507–6345].  
Standard dose groups: 18–55 years, 
median 9807 AU/mL [IQR 5847–17 
220], n=43; 56–69 years, 5496 
AU/mL [2548–12 061], n=55; ≥70 
years, 4156 [2122–12 595] 
At day 42 
Low-dose groups: 18–55 years, 
median 161 [IQR 99–233], n=41; 
56–69 years, 143 [79–220], n=28; 
≥70 years, 150 [103–255].  
Standard dose groups: 18–55 years, 
median 193 [IQR 113–238], n=39; 
56–69 years, 144 [119–347], n=20; 




protein peaked 14 days 
after the prime 
vaccination  
Standard-dose groups: 
18–55 years, median 
1187 spot forming cells 




2428], n=24; 56–69 
years, 797 SFCs [383–
ChAdOx1 nCoV-19 appears to be better 
tolerated in older adults than in younger 
adults and has similar 
immunogenicity across all age groups 




1817], n=29; and ≥70 
years, 977 SFCs [458–
1914]. 
Xia, et al. 
[20] 











- - The inactivated SARS-CoV-2 vaccine, 
BBIBP-CorV, is safe and well tolerated at 
all tested doses in two age groups. Rapid 
humoral responses against SARS-CoV-2 
were noted from day 4 after first 
inoculation and 100% seroconversion was 
found in all participants on day 42. 
Xia, et al. 
[20] 














































































Adverse events associated with 
the 
mRNA-1273 vaccine were 
mainly mild or moderate. The 
100-μg dose induced 
higher binding- and 
neutralizing-antibody titers than 
the 25-μg dose. 
Keech, et 
al. [22] 
Gp-A: 113.5(93.6-137.6);  
Gp-B: 575.5 (331.7- 998.5);  
Gp-C: 63160 (47117.3- 84666);  
Gp-D: 47521 (33803.7- 66804.6);  
Gp-E: 2932 (1987.7- 4324.8) 
Gp-A: 20.0 (20.0-20.0);  
Gp-B: 41.4 (27.5- 62.4);  
Gp-C: 3906.3 (2555.9- 5970.0);  
Gp-D: 3305 (2205.3- 4953.2);  




CD4+ T-cell responses 
that were reflected in 
IFN-γ, IL-2, and TNF-
α production on spike 
protein stimulation. 
At 35 days, NVX-CoV2373 appeared to 
be safe, and it elicited immune responses 
that exceeded levels in Covid-19 
convalescent serum. 
Mulligan, 
et al. [23] 
At day 28 
10-μg dose: 4,813 U ml−1 
30-μg dose: 27,872 U ml−1 
100-μg dose: 1,260 U ml−1 
14 days after the second dose 
180 (10-μg dose level) and 437 (30-
μg dose level) 
- These results support further evaluation 




18–55 Years of Age (Day 35) 
10 μg (5120U/ml) 20 μg (7480U/ml) 
30 μg (13940U/ml) 
65–85 Years of Age (Day 35) 
10 μg (1527U/ml) 20 μg (6399U/ml) 
30 μg (4798U/ml) 
 
BNT162b2 
18–55 Years of Age (Day 35) 
10 μg (4717U/ml) 20 μg (7367U/ml) 
30 μg (8147U/ml) 
65–85 Years of Age (Day 35) 
10 μg (3560U/ml) 20 μg (2656U/ml) 
30 μg (6014U/ml) 
The highest neutralization titers 
were measured in samples obtained 
on day 28 (i.e., 7 days 
after the second dose) or on day 35 
(i.e., 14 days after the second dose). 
- BNT162b2 for advancement to a 




Phase 1 trial  
3 μg group (465·8 [288·1–753·1]) 
versus 24 (100%) in the 6 μg group 
(1395·9 [955·2–2039·7]) versus two 
(8%) in the placebo group (89·8 
[76·1–105·9]) at 28 days after the 
second dose in the days 0 and 14 
vaccination. 
 
Phase 2 trial 
3 μg group (GMT 1094·3 [95% CI 
936·7–1278·4]) versus 118 (100%) of 
118 participants in the 6 μg group 
(1365·4 [1160·4–1606·7]) 
versus none of 56 participants in the 
placebo group (81·0 [79·0–83·0]) at 
14 days after the second dose. 
Phase 1 trial 
3 μg group (5·4 [3·6–8·1] versus 20 
(83%) in the 6 μg group (15·2 
[11·2–20·7]) versus none in the 
placebo group (2·0 [2·0–2·0]) 
at 28 days after the second dose. 
 
Phase 2 trial 
3 μg group (23·8 [20·5–27·7]) 
versus 117 (99%) of 118 in the 6 μg 
group (30·1 [26·1–34·7]) versus 
none of 60 in the placebo group (2·0 
[2·0–2·0]) at 28 days after the 
second dose in the day 0 and 14 
vaccination cohort 
Phase 1 trial 
3 μg group, 1·2 (0·5 to 
1·8) in the 6 μg group, 
and 1·2 (–0·1 to 2·5) in 
the placebo group for 




Taking safety, immunogenicity, and 
production capacity into account, the 3 μg 
dose of CoronaVac is the suggested dose 








18–55 Years of Age (Day 35) 
10 μg (4717U/ml) 20 μg (7367U/ml) 
30 μg (8147U/ml) 
65–85 Years of Age (Day 35) 
10 μg (3560U/ml) 20 μg (2656U/ml) 
30 μg (6014U/ml) 
- - Two 30-μg doses of BNT162b2 elicited 
high SARS-CoV-2 neutralizing antibody 
titers and robust antigenspecific CD8+ 
and Th1-type CD4+ T-cell responses. 
The 50% neutralizing geometric mean 
titers elicited by 30 μg of BNT162b2 in 
older and younger adults exceeded the 
geometric mean titer measured in a 
human convalescent serum panel, despite 
a lower neutralizing response in older 
adults than in younger adults. 
Che, et al. 
[27] 
Seroconversion rates in the medium- 
and high-dose groups were 89% and 
96%, respectively, with GMTs of 23 
and 30, respectively, at day 14 after 
immunization, and 92% and 96% 
with GMTs of 19 and 21, 
respectively, at day 28 after immu - 
nization 
approximately 60% seroconversion 
with GMTs of 387 and 434 at day 
14 for the 0, 14 procedure and 
approximately 50% seroconversion 
with GMTs of 342 and 380 at day 
28 
- Immunogenicity of this vaccine induced a 
neutralizing antibody response in 95% of 
the adult population aged 18–59 years, 
but also that the vaccine had the capacity 





The systematic review (14 studies) and meta-analysis (12 
studies) on COVID-19 vaccines provide the best available 
evidence that the candidate COVID-19 vaccines are associated 
with the risk of solicited systemic adverse events and 
unsolicited systemic adverse events. Our findings suggest that 
it is essential to account for the adverse events while conducting 
and implementing the COVID-19 vaccine trials. To date, there 
is no systematic review on this topic, and most of the earlier 
reviews are limited in that they have not provided any evidence 
for adverse events of COVID-19 vaccines. It is important to 
inform the adverse events of the current COVID-19 pandemic. 
Previous data from randomized trials are with a smaller sample 
size comprising different populations and vaccines. 
According to the forecasting and fattening of curve theory, there 
are reduced chances to develop an effective vaccine that can 
affect the first wave of the COVID-19 pandemic. However, the 
development of a vaccine in the near future will be useful to 
prevent subsequent infection waves that may occur later as a 
seasonal SARS-CoV-2 virus that is supposed to persist in the 
post-pandemic phase. As COVID-19 is a novel infection, the 
possible duration of acquired immunity remains unclear, and so 
is the immunization schedule. Hence, whether single-dose 
vaccines will confer immunity or require subsequent booster 
doses can only be ascertained in the future. 
Considerations for a potential COVID-19 vaccine 
Phylogenetic analysis of SARS-CoV-2 revealed around 89% 
nucleotide sequence homology with bat SARS-like 
coronaviruses (genus Betacoronavirus) identified from China 
[28]. Therefore, the potential strategies for SARS-CoV-2 
vaccine should be guided with the earlier research on vaccine 
development for other coronaviruses such as SARS (severe 
acute respiratory syndrome) and MERS (Middle East 
respiratory syndrome) [29]. Unfortunately, various obstacles 
are causing the lack of effective vaccine development for the 
earlier SARS coronaviruses. One of them is the hyperimmune 
response manifested as eosinophilic infiltration or enhanced 
infectivity post-immunization with vaccines based on the whole 
virus or complete spike protein [30]. The mechanism of 
immunopotentiation is not unusual as a similar response was 
also reported with a whole virus vaccine for the respiratory 
syncytial virus (RSV), and these findings are still under 
investigation [30]. Thus, full safety considerations should be 
given to avoid any hyperimmune response for a targeted 
COVID-19 vaccine.  
Moreover, research on vaccine development for other 
coronaviruses does not attract much interest and funding due to 
relatively lower incidence, and the infection is confined to a 
specific geographic region [29]. Also, preclinical trials for a 
candidate vaccine require appropriate funding to conduct 
studies on small animal models, which was a limiting factor for 
the previous sporadic outbreaks. Therefore, the development of 
an effective vaccine for the COVID-19 pandemic is crucial, 
considering the undesired immunopotentiation, suitability, and 
availability for healthcare professionals. The availability and 
suitability for vulnerable populations such as the elderly, 
pediatrics, or individuals with underlying comorbidities are 
poignant factors that must be addressed for a potential COVID-
19 vaccine [31]. 
To date, there are three major categories of candidate vaccines, 
namely the Whole Virus Vaccines (inactive or live-attenuated), 
Subunit vaccines (recombinant), and nucleic acid vaccines 
(DNA and RNA) [32]. Out of these available options, vaccines 
based on nucleic acid have tremendous potential for success and 
rapid development, seconded by the recombinant-subunit 
vaccines. Genetic vaccines (DNA or RNA) or viral vector-
based vaccines are simple in composition, easy to handle, and 
readily taken up and translated into protein by host cells, which 




vaccines is quick production at a lower cost and has the 
potential to meet the requirements of mass production in a 
pandemic. Similarly, DNA vaccine benefits include easy 
upscaling, low manufacturing cost, high thermal stability, and 
proven results for human SARS-CoV-1. In addition, it has a 
better safety profile and enhanced immunogenicity when 
compared to other types of vaccines [33-35]. Also, it provides 
useful preclinical and clinical data to be benchmarked for other 
emerging coronaviruses including, MERS-CoV. RNA vaccine 
development requires genetic engineering of RNA to attain a 
strong expression of the viral antigen [33,34].  
On the other hand, the neutralizing antibody response to 
recombinant-subunit vaccines can affect clinical efficacy. 
However, nucleic acid vaccines are not generally subject to such 
antibody reactions. Moreover, it eliminates the possibility of an 
immunodominant response to the desired transgene product. 
The major drawback is that the vector immunity might 
negatively influence vaccine effectiveness depending upon 
vector selection [36]. Also, such vaccines necessitate specific 
delivery devices to induce desirable immunogenicity. 
The classical vaccination strategy for viral infections mainly 
includes whole virus vaccines, which constitute either live-
attenuated or inactive whole virus. The live-attenuated vaccines 
are preferred as the production process is straight-forward with 
existing infrastructure and can be benchmarked from various 
licensed human vaccines. However, the development of 
infectious attenuated clones of coronavirus for vaccination is a 
challenging and time-consuming process that depends on the 
length of the viral genome and requires extensive testing for 
safety and efficacy. Like live attenuated vaccines, the inactive 
vaccines can be manufactured using the established 
infrastructure and production processes available for other 
licensed human vaccines for SARS-CoV-1, together with 
adjuvants that can enhance the vaccine's immunogenicity. 
Nevertheless, the major challenge is handling the massive 
amounts of infectious virus, which can be overcome by using 
an attenuated seed virus. Another difficulty is to confirm the 
integrity of the antigen or epitope postproduction.  
The other type of vaccine candidate for SARS coronaviruses 
and COVID-19 is the subunit vaccines that trigger an immune 
response against the spike protein of the virus that prevents its 
binding with the host's ACE2 receptor and blocks viral entry. 
The primary advantage of recombinant protein vaccines is the 
ease of handling non-infectious particles and the feasibility to 
use adjuvants that enhance the immunogenicity. However, such 
vaccines might have limited mass production capacity, and it is 
challenging to maintain the integrity of the antigen or epitope 
with high yields.  
Worldwide, scientists are working to formulate a robust 
COVID-19 vaccine rapidly [37]. However, for scientists and 
physicians, the term "warp speed" should be a matter of concern 
and scientific research necessitates rigor, discipline, and 
deliberate caution. Under normal circumstances, the 
commercialization of any vaccines may take 5-10 years. 
However, this timeline has been hastened during this pandemic 
to 12-18 months, including the period for evaluation and 
confirmation of safety, efficacy, stability, dosage, scalability, 
and manufacturability. This projection will have to be refined 
over time, and it is assumed to be one to one and a half years if 
everything goes smoothly from the point of identifying the 
vaccine. The process includes small-scale manufacturing for 
phase I, II, and III clinical trials, followed by regulatory 
approval and large-scale manufacturing.  
During a pandemic, the goal is to compress this timeline for 
vaccine development and commercialization without impacting 
safety, which remains critical since the vaccine will be given to 
a large number of people. Great ideas are not often translated 
into viable vaccines due to various factors, including reliable 
scale-up manufacturing or problems during the regulatory 
approval phase. The manufactured product should be enough to 
provide the desired dosage and high quality and undergo a 
robust and consistent process. Currently, there are several 
vaccine candidates in this race. However, the manufacturing 
facility requirement varies from type of vaccine production. 
Therefore, when the winners are announced, the challenge is to 
secure multiple manufacturing facilities to produce that 
particular type of vaccine, and there will not be time for 
alteration. 
Notably, any investigational product approved for mass 
immunization with compromised safety assessment can cause 
harm. Therefore, it is essential to develop public trust for 
vaccination trials as volunteers for COVID-19 prevention 
efforts worldwide. As the quest for an effective SARS-CoV-2 
vaccine increases, researchers involved in the developmental 
process should maintain public trust and not initiate a vaccine 
trial that either has undermines the standard safety regulations 
or trials incepted with serious technical loopholes [38]. The 
safety and efficacy of the COVID-19 vaccine are of the utmost 
consideration due to the shorter development and testing 
process. So there might be an underlying suspicion about the 
effectiveness of vaccines among some segments of the 
population. For instance, the Phase-3 trial of COVID-19 by 
AstraZeneca-Oxford University is put on hold after the 
suspected adverse reaction in study participants from the United 
Kingdom [39].  
Moreover, there are additional challenges and concerns in 
conducting clinical trials at the time of an ongoing pandemic. It 
is impossible to predict the location and timing of an infectious 
outbreak during an epidemic. So it is challenging to select the 




testing. Besides, in places where the fatality rate is high, running 
of randomized controlled trials with a placebo arm may not be 
feasible due to the higher risk of poor outcomes and ethical 
aspects. On the other hand, scientific approaches that considers 
such as aspects as mentioned earlier, may not be speedy to 
develop vaccines but are scientifically feasible. However, the 
results can be harder to interpret [40,41]. Recently, the World 
Health Organization (2019) mentioned that the reluctance or 
refusal of available vaccines is considered one of the major 
global health threats and humanitarian crises worldwide [42]. 
Despite pioneering techniques used for speedy vaccine 
development in this emergency, it is estimated that the 
development of an effective vaccine with appropriate safety and 
efficacy will take at least 12-18 months for mass production and 
availability [43]. 
The main strength of this review is associated with its adherence 
to established methodological features, along with a 
comprehensive search strategy, public and transparent protocol 
and meticulous evaluation procedures. Conversely, a significant 
limitation lies in the differences in study design and 
heterogeneity between included studies, despite our strict 
inclusion criteria, probably reflecting the age range, settings, 
and vaccine types across different studies. Finally, the present 
comprehensive systematic review provides the best available 
information on solicited systemic adverse events and 
unsolicited systemic adverse events of the COVID-19 vaccine. 
At the same time, contemporary evidence on immunogenicity 
and efficacy is being generated. 
Expert opinion 
The current global pandemic caused by the COVID-19 
represents an unprecedented risk, as millions of lives are at 
stake. The development of a vaccine to circumvent the high 
death tolls is of paramount importance. This coronavirus virus 
strain is novel and unique in its genetic makeup, proving 
foremost pharmaceutical companies a challenge for a definitive 
answer. The driving force behind the COVID-19 vaccine 
development is its high infectivity, which affects a vast host of 
individuals, especially vulnerable populations, i.e. elderly and 
individuals with concomitant comorbidities. For this reason, the 
pharmaceutical conglomerates and global leaders in 
immunology have incepted a unified international clinical trial 
known as "Solidarity" (ISRCTN83971151). This aims to 
catapult the synthesis and development of a reliable, safe, and 
cost-effective vaccine. The current ongoing clinical trials for 
vaccine development show promising results concerning the 
candidate DNA and RNA vaccines. Further research and 
development from this finding will render a potential answer 
and cure to the current woes and perils experienced by the 
global healthcare fraternities due to this pandemic.  
The real-world implications of this vaccine being a success will 
be multi-faceted in nature as a vaccine of this design will save 
countless lives and simultaneously bode positive effects on a 
proverbial geo-economic disaster caused by stringent lockdown 
regulations that prohibit trade and business activities. The effect 
of such a vaccine can therefore be holistically summarized on 
both a humanitarian and financial basis. The implication of such 
a vaccine in real-world clinical practice is very likely as the 
resources for such an endeavor have now been made available 
due to the extreme need for a vaccine. This juxtaposes abundant 
resources with a serious lack of time.  Unlike the past where 
vaccine development for previous strains of coronavirus 
suffered from lack of funding, but ample time. The 
repercussions of the dearth in knowledge and lack of an 
effective vaccine for the previous coronaviruses are implicated 
in the delay of the current vaccine development.  
The major limitation in the current scenario is time constraints; 
thereof, the urgency for such a vaccine to be produced is 
unnerving and renders a fine line between speed, safety, and 
efficacy of the vaccine. Notably, a vaccine's safety must be the 
prerogative, and no time constraints or external influences 
should cloud the integrity of the scientific method. A vaccine 
with inferior safety and efficacy parameters could pose more 
threats to people’s lives than the actual virus does. There is still 
an unfathomable amount of exploration and research that needs 
to be conducted in this field. In the future, the first commercially 
available vaccine will need further evaluation with post-
marketing drug surveillance via phase IV studies. Furthermore, 
pre-emptive vaccines should be synthesized, considering the 
different infection waves and genetic variability of the viral 
strains. 
The future of the coronavirus vaccination development is 
dynamic that needs continuous research on how it can be 
prevented and circumvented in the future with the use of 
standard vaccination programs and will eventually require the 
development of new vaccines for the SARS-CoV-2 virus family 
on a cyclical basis like that of the influenza virus. 
 
Conclusion 
This systematic review and meta- analysis findings invite a 
revisit to the reported solicited systemic adverse events and 
unsolicited systemic adverse events for COVID-19 candidate 
vaccines. The question in a pandemic is: "Can we justify 
exposing many people to COVID-19 candidate vaccines at 
phase-3 trails?",  especially since many such vaccines appear to 
have adverse events and as yet insufficient evidence on safety 
and effectiveness. Moreover, further longitudinal studies are 
needed to better understand the effectiveness of the COVID-19 
vaccine for long-term immunogenicity. Currently, there is an 




19 and potential therapeutic interventions for treatment. 
Moreover, the COVID-19 immunization should be accessible 
to the public as soon as rigorous testing has confirmed the safety 
and efficacy of the potential vaccine. Upon the development of 
an effective vaccine, physicians, nurses, and other frontline 
health care professionals will play a vital role in the mass' 
encouragement of COVID-19 vaccination in the community. 
The vaccination programs should be developed for equitable 
and judicious use, targeting frontline healthcare professionals 
and high-risk individuals during the initial phase of vaccine 
availability, which may be limited. We also need to ensure an 
equal distribution of vaccines across high- and low-income 
countries to unsure nobody and no countries stays behind in our 
fight against COVID-19.  It is the responsibility of health 
regulatory authorities not to endorse a candidate vaccine 
without sufficient information. The likelihood of achieving 
public acceptance will depend on scientific evidence based on 
high-quality trials to endorse the safety and efficacy of the 
proposed vaccine. The long-term objective of COVID-19 
prevention relies on implementing a universal vaccination 
program with proven safety, efficacy, and cost-effectiveness, 
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